hotspot -WSS

hotspot

author：knowledge 2025-10-02 21:04:57 - browse：2479

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Obamacare plans could cover weight loss drugs

Wikipedia

WSS

First Opinion Podcast: Long Covid needs a new approach

Hospital price transparency does save money, advocate argues

Researchers explore possible ties between long Covid, menopause

FDA warns medical device makers about rise in fabricated data

Researchers tackle phage therapy hurdles for wider adoption

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

leisure time

hotspot

The contrarian view of Viking Therapeutics

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA warns J&J's Abiomed: We will regulate your software

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Researchers explore possible ties between long Covid, menopause

Virginia high school admissions case could be legal follow

Eli Lilly expects to double planned employment in Boston center

Anesthesiologist group: stop taking Ozempic before surgery

MD Anderson's Padmanee Sharma responds to research credit suit

In Memoriam: Notable people who died in 2023

Impact of Dobbs ruling felt at reproductive medicine meeting

explore

UnitedHealth’s board chair also owns a personal investment firm

Abridge raises $150m as clinical notes automation market heats up

CEOs share strategies for surviving biotech slump

CEOs share strategies for surviving biotech slump

Abridge raises $150m as clinical notes automation market heats up

The EU Joint Clinical Assessment needs to live up to its promise

hotspot

Wikipedia

leisure time

focus